Ovid Therapeutics Inc (OVID)

$2.56 +0.26 (11.30%)
Market Cap 303.31M
Revenue (ttm) 7.25M
Net Income (ttm) -17.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -240.14%
Debt to Equity Ratio 0.00
Volume 6,225,100
Avg Vol 3,002,776
Day's Range N/A - N/A
Shares Out 131.88M
Stochastic %K 90%
Beta -0.03
Analysts Strong Sell
Price Target $4.71

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the tr...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 661 7661
Fax: 646 661 4027
Address:
Hudson Commons, 441 9th Avenue 14th Floor, New York, United States
lucabrix
lucabrix Apr. 7 at 7:56 PM
$OVID Reply!
0 · Reply
StockConsultant
StockConsultant Apr. 7 at 6:48 PM
$OVID Ovid Therapeutics stock, nice setup and rally off the 2.15 support area, watch for a breakout, volume +261% at https://stockconsultant.com/?OVID
0 · Reply
signaljumper
signaljumper Apr. 7 at 6:05 PM
$OVID a Break of 2.70 and WE will fly
0 · Reply
DailyRocketPicks
DailyRocketPicks Apr. 6 at 7:34 PM
$OVID adding here at 2.30. Target set at 2.37
0 · Reply
michaelhearn
michaelhearn Apr. 6 at 5:55 PM
$OVID added today and happy I did. Looking very strong here
0 · Reply
signaljumper
signaljumper Apr. 6 at 5:34 PM
$OVID a Close above 2.46 in the coming days give the Bulls space to the next target of 3.12
0 · Reply
michaelhearn
michaelhearn Apr. 6 at 2:27 PM
$OVID added
0 · Reply
HedgedMyFeelings
HedgedMyFeelings Apr. 6 at 2:11 PM
$OVID Added
0 · Reply
michaelhearn
michaelhearn Apr. 4 at 7:03 PM
$OVID drop on 100 shares. Manipulation at its fonest
0 · Reply
Sanderstein
Sanderstein Apr. 4 at 5:18 PM
$OVID What is the massive drop after hours?
0 · Reply
Latest News on OVID
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Mar 18, 2026, 10:01 AM EDT - 20 days ago

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 18, 2026, 6:05 AM EDT - 20 days ago

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Mar 18, 2026, 6:00 AM EDT - 20 days ago

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Feb 25, 2026, 7:00 AM EST - 5 weeks ago

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Dec 18, 2025, 8:00 AM EST - 3 months ago

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Dec 2, 2025, 7:00 AM EST - 4 months ago

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 5 months ago

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Oct 3, 2025, 7:05 AM EDT - 6 months ago

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Oct 3, 2025, 7:00 AM EDT - 6 months ago

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Aug 13, 2025, 8:00 AM EDT - 8 months ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Jul 23, 2025, 8:30 AM EDT - 9 months ago

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Jun 25, 2025, 8:00 AM EDT - 10 months ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 11 months ago

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:15 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 12, 2024, 11:55 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm

Aug 9, 2024, 9:15 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm

Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm

Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 11:30 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm

Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Aug 2, 2024, 10:00 AM EDT - 1 year ago

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

Jun 17, 2024, 8:58 AM EDT - 1 year ago

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

TAK

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

Jun 17, 2024, 6:55 AM EDT - 1 year ago

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

May 14, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Mar 8, 2024, 8:00 AM EST - 2 years ago

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 8:00 AM EST - 2 years ago

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Dec 1, 2023, 7:30 AM EST - 2 years ago

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

lucabrix
lucabrix Apr. 7 at 7:56 PM
$OVID Reply!
0 · Reply
StockConsultant
StockConsultant Apr. 7 at 6:48 PM
$OVID Ovid Therapeutics stock, nice setup and rally off the 2.15 support area, watch for a breakout, volume +261% at https://stockconsultant.com/?OVID
0 · Reply
signaljumper
signaljumper Apr. 7 at 6:05 PM
$OVID a Break of 2.70 and WE will fly
0 · Reply
DailyRocketPicks
DailyRocketPicks Apr. 6 at 7:34 PM
$OVID adding here at 2.30. Target set at 2.37
0 · Reply
michaelhearn
michaelhearn Apr. 6 at 5:55 PM
$OVID added today and happy I did. Looking very strong here
0 · Reply
signaljumper
signaljumper Apr. 6 at 5:34 PM
$OVID a Close above 2.46 in the coming days give the Bulls space to the next target of 3.12
0 · Reply
michaelhearn
michaelhearn Apr. 6 at 2:27 PM
$OVID added
0 · Reply
HedgedMyFeelings
HedgedMyFeelings Apr. 6 at 2:11 PM
$OVID Added
0 · Reply
michaelhearn
michaelhearn Apr. 4 at 7:03 PM
$OVID drop on 100 shares. Manipulation at its fonest
0 · Reply
Sanderstein
Sanderstein Apr. 4 at 5:18 PM
$OVID What is the massive drop after hours?
0 · Reply
Nosh
Nosh Apr. 2 at 7:35 PM
$OVID Added.
0 · Reply
moneygrabber55
moneygrabber55 Apr. 2 at 5:08 PM
$OVID anybody here?
0 · Reply
Big_Zack22
Big_Zack22 Mar. 31 at 1:35 PM
$OVID
0 · Reply
luccichio
luccichio Mar. 30 at 6:13 PM
$OVID Ctmx did this same dip around the same level, and it scared me out. Not making that mistake with this one.
0 · Reply
michaelhearn
michaelhearn Mar. 26 at 4:12 PM
$OVID strong
0 · Reply
Yimmiedd
Yimmiedd Mar. 25 at 5:11 PM
$OVID odd PA there
0 · Reply
CrispDry
CrispDry Mar. 25 at 5:00 PM
$OVID what’s the volume on that candle?
0 · Reply
signaljumper
signaljumper Mar. 25 at 4:57 PM
$OVID a Close above 2.70 and we will See the Gap Close at 3.12
0 · Reply
michaelhearn
michaelhearn Mar. 24 at 6:10 PM
$OVID added
0 · Reply
signaljumper
signaljumper Mar. 23 at 12:08 PM
$OVID broke the Long therm downtrend. Gap Close in play 3.12 target
0 · Reply
luccichio
luccichio Mar. 23 at 11:30 AM
$OVID ride the wave. Only way to go is up.
0 · Reply
FriendOfmy
FriendOfmy Mar. 23 at 6:09 AM
$OVID $2.00 incoming today imo. Offering at 2.01?!!!! Only way is down until diltuter is done collection his payment.
0 · Reply